Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gujarat Kidney And Super Speciality's EBIT per Share for the
three
months ended in Mar. 2026 was ₹0.88.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹3.40.
During the past 12 months, the average EBIT per Share Growth Rate of Gujarat Kidney And Super Speciality was 112.60% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 34.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
NSE:GKSL'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 34.4 Med: 34.4 Max: 34.4
Current: 34.4
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Gujarat Kidney And Super Speciality was 34.40% per year. The lowest was 34.40% per year. And the median was 34.40% per year.
NSE:GKSL's 3-Year EBIT Growth Rate is ranked better than 75.48% of 526
companies
in the Healthcare Providers & Services industry
Industry Median: 12.05
vs NSE:GKSL: 34.40
Gujarat Kidney And Super Speciality (NSE:GKSL) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Gujarat Kidney And Super Speciality EBIT per Share Related Terms
Gujarat Kidney And Super Speciality EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Kidney And Super Speciality EBIT per Share Chart
Gujarat Kidney And Super Speciality Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
EBIT per Share
1.51
2.02
1.70
3.71
Gujarat Kidney And Super Speciality Quarterly Data
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Kidney And Super Speciality (NSE:GKSL) has a EBIT per Share of ₹3.40 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Gujarat Kidney And Super Speciality and its competitors. According to the industry distribution chart, Gujarat Kidney And Super Speciality ranks #129 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 24.5%.
Is Gujarat Kidney And Super Speciality's EBIT per Share too high?
Gujarat Kidney And Super Speciality's current EBIT per Share is ₹3.40. Based on the distribution chart, Gujarat Kidney And Super Speciality ranks #129 out of 526 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Gujarat Kidney And Super Speciality has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Gujarat Kidney And Super Speciality's EBIT per Share compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Gujarat Kidney And Super Speciality ranks #129 out of 526 companies for EBIT per Share. This places Gujarat Kidney And Super Speciality in the top 25% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 12.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.05, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Gujarat Kidney And Super Speciality and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gujarat Kidney And Super Speciality's current EBIT per Share is ₹3.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Kidney And Super Speciality stock overvalued right now?
Gujarat Kidney And Super Speciality (NSE:GKSL) has a current EBIT per Share of ₹3.40. The current EBIT per Share is ₹3.40. Gujarat Kidney And Super Speciality's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Gujarat Kidney And Super Speciality (NSE:GKSL), the current EBIT per Share is ₹3.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gujarat Kidney And Super Speciality Business Description
Gujarat Kidney And Super Speciality Ltd is engaged in the business of operating a chain of mid-sized multispeciality hospitals in central Gujarat and providing integrated healthcare services, with a focus on secondary and tertiary care. It offers a range of healthcare services, including General Medicine, General Surgery, Laparoscopic Surgery, Urology, Cardiology, Nephrology, and many more. The company operates in a single segment, namely Medical and Healthcare Services. It generates a substantial portion of revenue from its services to inpatients. Geographically, it operates only in India.
18GF Score
Get the complete analysis for NSE:GKSL
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GKSL has been successfully added to your 
